{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:09:18Z","timestamp":1753891758882,"version":"3.41.2"},"reference-count":5,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2022.1004853","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T05:07:30Z","timestamp":1662008850000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Autoantibodies in post-treatment Lyme disease syndrome"],"prefix":"10.3389","volume":"13","author":[{"given":"Armin","family":"Alaedini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary P.","family":"Wormser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"874211","DOI":"10.3389\/fneur.2022.874211","article-title":"Peptidylarginine deiminase 2 autoantibodies are linked to less severe disease in multiple sclerosis and post-treatment Lyme disease","volume":"13","author":"Kim","year":"2022","journal-title":"Front Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1172\/JCI78084","article-title":"Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity","volume":"125","author":"Suurmond","year":"2015","journal-title":"J Clin Invest."},{"key":"B3","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nrrheum.2013.30","article-title":"Protective autoantibodies in the rheumatic diseases: lessons for therapy","volume":"9","author":"Silverman","year":"2013","journal-title":"Nat Rev Rheumatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.bbi.2010.03.002","article-title":"Anti-neural antibody reactivity in patients with a history of Lyme borreliosis and persistent symptoms","volume":"24","author":"Chandra","year":"2010","journal-title":"Brain Behav Immun."},{"key":"B5","doi-asserted-by":"publisher","first-page":"5417","DOI":"10.1038\/s41467-021-25509-3","article-title":"New-onset IgG autoantibodies in hospitalized patients with COVID-19","volume":"12","author":"Chang","year":"2021","journal-title":"Nat Commun."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1004853\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T05:07:32Z","timestamp":1662008852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1004853\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":5,"alternative-id":["10.3389\/fneur.2022.1004853"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.1004853","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2022,9,1]]},"article-number":"1004853"}}